Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 219.84% Potential Upside Awaits Investors
Niagen Bioscience, Inc. (NAGE) is highlighted as a compelling investment opportunity in the healthy aging product sector, with analysts projecting a significant upside potential of 219.84%. The company, known for its nicotinamide riboside ingredient, exhibits strong financial metrics such as a 32.90% revenue growth rate and a 38.90% return on equity. Despite current stock performance below moving averages, strong analyst consensus and a focus on reinvesting earnings for growth suggest long-term success.
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen
Niagen Bioscience announced its role as the premiere sponsor for the inaugural "NAD for Health: Opportunities & Challenges" conference hosted by the University of Copenhagen, scheduled for March 23-25, 2026. This scientific forum aims to advance NAD+ (nicotinamide adenine dinucleotide) science by fostering dialogue among experts from various disciplines. The conference will address the translation of NAD metabolism research into clinical applications, focusing on trial design, biomarkers, and regulatory considerations, with themes including NAD+ precursor strategies for orphan diseases and neurodegenerative diseases.
Niagen Bioscience is the Premiere Sponsor of the Inaugural "NAD for Health: Opportunities & Challenges" Conference Hosted by the University of Copenhagen
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its premiere sponsorship of the inaugural "NAD for Health: Opportunities & Challenges" scientific meeting, hosted by the University of Copenhagen. This three-day conference, scheduled for March 23-25, 2026, will gather leading NAD experts to foster evidence-based dialogue and accelerate clinical translation in NAD metabolism and its implications for human health. The event aims to address barriers to translation in NAD science, including trial design, biomarkers, and regulatory considerations.
Niagen Bioscience Sponsors Inaugural NAD for Health Conference
Niagen Bioscience is the primary sponsor of the first "NAD for Health: Opportunities & Challenges" scientific meeting in Copenhagen from March 23-25, 2026. This conference aims to advance NAD+ science and healthy aging research by bringing together experts to discuss NAD metabolism, rare diseases, healthspan extension, and neurodegenerative diseases. The event will include thematic sessions, a panel discussion, and a dedicated poster session, with a global livestream to ensure broad access to the latest research.
Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?
Niagen Bioscience (NAGE) is preparing for its Q4 and fiscal 2025 earnings call on March 4, 2026, where it will provide a business update on its leading NAD+ franchise, Niagen®. The company's investment narrative heavily relies on its patented Niagen® and FDA-recognized safety, with the upcoming call crucial for reinforcing or challenging its sales growth and margin improvements. Despite a recent stock price slide, Niagen Bioscience maintains a strong regulatory moat and product pipeline momentum, though reliance on a single molecule presents a concentration risk for investors.
A Look At Niagen Bioscience (NAGE) Valuation As New Partner Launches And Clinical Data Gain Attention
Niagen Bioscience (NAGE) has seen its stock valuation come under scrutiny despite recent excitement over new partner launches and clinical data for its FDA-recognized nicotinamide riboside. While the stock has experienced short-term declines, its 3-year total shareholder return remains robust. The company is considered 68% undervalued with a fair value of $16.04 per share, contingent on future growth, profitability assumptions, increased R&D, and successful pharmaceutical developments.
Institutional Owners May Consider Drastic Measures as Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Recent US$69m Drop Adds to Long-term Losses
Institutional investors hold a significant 39% stake in Niagen Bioscience, Inc., making them highly influential in the company's share price dynamics. A recent 14% drop in stock price, resulting in a US$69 million market cap fall and adding to a 9.8% one-year loss, may prompt these institutions to sell off shares. While institutional presence lends credibility, investors should also consider analyst sentiments and insider ownership, with insiders holding a notable US$130 million worth of shares.
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced it will host a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025. The company specializes in NAD+ science and healthy aging, offering products like Tru Niagen®. Financial results will be released via press release after market close on the same day.
Niagen Bioscience, Inc. (NAGE): A Bull Case Theory
This article summarizes a bullish thesis on Niagen Bioscience, Inc. (NAGE), highlighting its strong intellectual property in NAD+ biology with its patented compound, Niagen, which has FDA recognition. The company's dual-channel strategy, robust patent defenses, and scientific credibility position it as a leader in healthy aging products, despite market confusion and regulatory risks. NAGE is seen as a unique, cash-generative play in the cellular health megatrend, supported by profitable operations and recurring revenue.
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Promising Upside with a 163.77% Potential
Niagen Bioscience, Inc. (NAGE) is highlighted as a promising biotechnology investment with a robust market cap of $478.04 million and an impressive 32.90% revenue growth, driven by its flagship product, TRU NIAGEN. Analysts are bullish on the company, projecting a 163.77% upside with an average target price of $15.80, supported by strong financial indicators like a 38.90% Return on Equity and $13.79 million in free cash flow. Despite short-term bearish trends indicated by moving averages and RSI, the company's focus on NAD+ precursor nicotinamide riboside and reinvestment into growth initiatives positions it for sustainable future growth in the healthy aging market.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Moderate Buy" by Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus "Moderate Buy" rating from five brokerages, with an average 1-year price target of $14.28. The company recently surpassed quarterly earnings and revenue expectations, reporting $0.05 EPS against an estimated $0.02, and revenues of $33.99 million versus $31.3 million. Insider activity shows CFO Ozan Pamir significantly increased his holdings in November, purchasing 4,465 shares, and institutional investors have also adjusted their positions.
Niagen Bioscience (NASDAQ:NAGE) Shares Down 3.4% - Here's What Happened
Niagen Bioscience (NASDAQ:NAGE) shares dropped 3.4% during mid-day trading to $6.03, with trading volume 21% below average. The company recently beat quarterly earnings estimates, and its CFO acquired additional shares, increasing insider ownership. Analyst sentiment for NAGE is a "Moderate Buy" with an average target price of $14.28, despite a recent downgrade by Canaccord Genuity Group.
Assessing Niagen Bioscience (NAGE) Valuation After New Truemed HSA And FSA Partnership
Niagen Bioscience (NAGE) is gaining investor attention following a partnership with Truemed, enabling customers to purchase Tru Niagen with HSA/FSA funds. Despite recent share price declines, the stock is considered undervalued by analysts, with a consensus price target of $16.04 compared to its current trading price of $6.03. The article highlights the potential for future growth based on expected earnings and profitability but also notes risks like competition and regulatory changes.
A Look At Niagen Bioscience (NAGE) Valuation After New HSA And FSA Purchasing Option For Tru Niagen
Niagen Bioscience (NAGE) recently announced a partnership with Truemed, allowing customers to use HSA and FSA funds for Tru Niagen purchases, drawing new attention to the company. Analysts believe NAGE is undervalued, with a fair value of US$16.04 compared to its recent close of US$6.19, citing potential future earnings growth from increased R&D and pharmaceutical developments. Despite recent share price declines, longer-term shareholder returns have been strong.
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.
Niagen Bioscience has partnered with Truemed to allow qualified customers to purchase Tru Niagen®, a leading NAD+ supplement, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. Customers can make these purchases with a Truemed Letter of Medical Necessity (LMN) on the Tru Niagen website, making the science-backed nutritional support more financially accessible. This initiative utilizes pre-tax health dollars for the purchase through a streamlined checkout process.
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
Niagen Bioscience has partnered with Truemed to allow qualified customers to purchase Tru Niagen®, a leading NAD+ supplement, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds. This initiative aims to increase accessibility to the science-backed supplement by enabling the use of pre-tax health dollars through a streamlined checkout process with a Truemed Letter of Medical Necessity. Tru Niagen contains Niagen® (nicotinamide riboside, or NR), which supports cellular energy and DNA repair.
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen By Investing.com
Niagen Bioscience (NASDAQ:NAGE) has announced that customers can now use Health Savings Account (HSA) and Flexible Spending Account (FSA) funds for purchases of its Tru Niagen product through its website. This initiative, in partnership with Truemed, aims to increase accessibility to its NAD+ supplement for cellular health, requiring a Letter of Medical Necessity (LMN). The company, with a valuation of $505 million, recently reported strong Q3 2025 earnings, surpassing analyst expectations, and acquired a comprehensive patent portfolio related to nicotinamide riboside.
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative?
Niagen Bioscience (NAGE) recently presented at the Lytham Partners Healthcare Investor Summit, aiming to clarify its direction in healthy aging bioscience. This appearance offered management a platform to discuss the company's strategy and the impact of its Niagen portfolio, especially in light of new clinical evidence and potential regulatory shifts. The company projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a substantial upside to its current price, though investors should consider the reliance on regulatory approvals.
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative?
Niagen Bioscience (NAGE) recently presented at the Lytham Partners Healthcare Investor Summit to clarify its direction in healthy aging bioscience. This presentation aimed to refine the company's investment narrative, particularly focusing on the broader adoption of pharmaceutical-grade Niagen and future regulatory outcomes. Clinical evidence, such as the Lancet eClinicalMedicine trial, was highlighted to support future product uptake, though regulatory approvals remain a key dependency for investors.
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen
Niagen Bioscience (NASDAQ:NAGE) announced that customers can now use Health Savings Account (HSA) and Flexible Spending Account (FSA) funds to purchase its Tru Niagen product, a NAD+ supplement. This move, facilitated by a partnership with Truemed and requiring a Letter of Medical Necessity, aims to increase accessibility for consumers seeking nutritional support for cellular health. The company, through recent developments, has also surpassed Q3 2025 earnings expectations, acquired key patents, and initiated a share repurchase program.
Precision Wealth Strategies LLC Makes New $1.53 Million Investment in Niagen Bioscience, Inc. $NAGE
Precision Wealth Strategies LLC has made a new $1.53 million investment in Niagen Bioscience, Inc., acquiring 163,675 shares, representing approximately 0.21% ownership. This comes as Niagen Bioscience beat Q3 expectations with strong EPS and revenue figures. Analysts currently hold a "Moderate Buy" consensus rating for the stock, despite a recent price target adjustment by Canaccord.
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Niagen Bioscience has acquired the core nicotinamide riboside (NR) patent portfolio from Queen's University Belfast, making the company the sole owner of this critical intellectual property. This acquisition strengthens Niagen Bioscience's leadership in NAD+ precursor IP, giving them greater control over the development and application of NR. The portfolio includes foundational composition-of-matter patents covering various NR salt forms and derivatives.
Niagen Bioscience secures full ownership of key NR patents
Niagen Bioscience has announced that it has secured full ownership of key Nicotinamide Riboside (NR) patents. This move is significant for the company as it strengthens its intellectual property portfolio concerning its flagship product. The full ownership is expected to solidify Niagen Bioscience's position in the longevity and anti-aging supplement market.
Niagen Bioscience acquires patent portfolio from Queen’s University Belfast
Niagen Bioscience has acquired a comprehensive patent portfolio covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast, consolidating intellectual property crucial for its NR business. This acquisition strengthens Niagen Bioscience's control over molecules for current and future pharmaceutical applications, adding to its existing intellectual property estate of over 90 patents. The company also recently reported strong third-quarter earnings for 2025 and announced a $10 million share repurchase program.
Niagen Bioscience (NAGE) secures full patent rights via new QUB deal
Niagen Bioscience, through its subsidiary ChromaDex, has entered a new assignment agreement with Queen's University Belfast (QUB), securing full patent rights to certain assets. This deal replaces previous joint ownership and license arrangements, with QUB assigning all rights to ChromaDex and releasing them from past royalty obligations through 2025. In exchange, ChromaDex will make a series of payments to QUB, including a one-time payment of $1,000,000 for accrued royalties through 2024, annual payments from 2026 to 2038, and additional one-time payments in 2035 and 2038.
Investors in Niagen Bioscience (NASDAQ:NAGE) have seen incredible returns of 320% over the past three years
Niagen Bioscience (NASDAQ:NAGE) shareholders have experienced a remarkable 320% return over the last three years, despite a recent 34% drop in share price. This growth is linked to the company's transition from sustained losses to profitability during this period. The article suggests that while recent performance might be unsettling, the long-term fundamentals suggest a positive outlook, emphasizing the importance of insider transactions and underlying company growth.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Rating of "Moderate Buy" from Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a "Moderate Buy" consensus rating from five brokerages, with an average 1-year price target of $14.28. The company recently reported an earnings beat, with EPS of $0.05 against an expected $0.02, and reported revenue of $33.99 million. Insider activity shows CFO Ozan Pamir increased his holding by over 150% in November.
A Look at Niagen Bioscience (NAGE) Valuation After New Skincare Launch and Long COVID Study Results
Niagen Bioscience (NAGE) is gaining attention after launching "Tru Niagen Beauty" and publishing peer-reviewed clinical evidence on Niagen's benefits for long COVID. Despite a recent stock pullback, its three-year shareholder return remains strong, leading to a narrative that the stock is 57% undervalued with a fair value of $16.04 due to anticipated growth in pharmaceutical-grade ingredients and e-commerce. However, intense market competition and supply chain issues pose risks, while its current P/E ratio suggests a more cautious valuation compared to industry averages.
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen
Niagen Bioscience has launched Tru Niagen® Beauty, the first NAD+ skincare supplement in the U.S. featuring Niagen (nicotinamide riboside). This supplement combines Niagen with astaxanthin, hyaluronic acid, grape seed extract, biotin, and Vitamin E to support healthy skin, hair, and nails from a cellular level. It is designed to be used with existing Tru Niagen products to enhance cellular vitality.
Earnings call transcript: Niagen Bioscience Q3 2025 beats forecasts, stock dips
Niagen Bioscience Inc. (NAGE) reported strong Q3 2025 results, with EPS of $0.05 against a forecast of $0.02 and revenue of $34 million exceeding the expected $30.83 million, driven by a 33% year-over-year growth. Despite this earnings beat, the company's stock experienced a 3.73% dip in after-hours trading, settling at $7.06. The company also revised its full-year revenue growth guidance to 25-30% and discussed the strategic importance of its Niagen Plus product line and upcoming telehealth platform.
Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Niagen Bioscience, Inc. recently exceeded Q3 revenue and profit forecasts, leading analysts to update their predictions. While revenue estimates for 2026 remained stable, earnings per share expectations saw a significant increase, indicating a more bullish outlook from analysts. Despite the improved earnings outlook, the consensus price target for NAGE remained unchanged.
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
Niagen Bioscience, Inc. announced strong financial results for the third quarter of 2025, with net sales increasing 33% to $34.0 million and Adjusted EBITDA rising 120% to $6.4 million. The company reaffirmed its full-year 2025 net sales outlook of 25% to 30% year-over-year growth, driven by key initiatives like the launch of the AboutNAD® platform and expansion of its pharmaceutical-grade Niagen Plus™ IV distribution. These achievements underscore Niagen Bioscience's leadership in NAD+ research and its commitment to evidence-based product development and market expansion.
Niagen Bioscience notches partial win in ad challenge
Niagen Bioscience scored a partial victory in an advertising challenge against competitor Reus Research LLC. While the National Advertising Division (NAD) found that Reus Research's claims of third-party testing were valid, other nutritional and health claims made by Reus Research were deemed unsupported. The challenge centered on products using different forms of NAD+ precursors for healthy aging.
National Advertising Division Finds Certain Reus Cata-Kor NAD+ Claims Supported; Recommends Others Be Modified or Discontinued
The National Advertising Division (NAD) has found some claims made by Reus Research LLC for its Cata-Kor NAD+ products to be supported, while recommending modification or discontinuation for others. This decision came after a challenge initiated by Niagen Bioscience Inc. The NAD identified issues with Reus's claims regarding ingredient content, purity, health benefits, influencer disclosures, and the repurposing of product reviews.
Is NAGE's Pullback A Second Chance For Investors?
Niagen Bioscience Inc. (NAGE), formerly ChromaDex Corp., is highlighted as a company pioneering healthy aging through NAD+ science. The article details NAGE's recent financial performance, including significant sales growth and profitability, driven by increased demand for its Niagen products and expanding clinical adoption. Despite a recent stock pullback from its 52-week high, the company has raised its full-year 2025 net sales guidance for the third time, indicating strong market validation and future confidence.
Is NAGE's Pullback A Second Chance For Investors? - RTTNews
Niagen Bioscience Inc. (NAGE), a company focused on healthy aging through NAD+ science, has experienced significant growth in sales and profitability, driven by its Niagen product lines. The company recently raised its full-year 2025 net sales guidance for the third time and analysts are suggesting that the recent pullback in stock price could be a new investment opportunity for investors with the third-quarter financial results expected soon. NAGE, formerly ChromaDex Corp. (CDXC), reached a 52-week high of $14.69 and currently trades near $7.50.
Niagen Bioscience's Pharmaceutical-Grade Niagen IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
Niagen Bioscience's pharmaceutical-grade Niagen IV and injections are now available at over 50 iCRYO clinics and more than 900 total clinics nationwide. This partnership aims to provide accessible, preventative solutions for health and vitality by boosting NAD+ levels, which decline with age and stress. Niagen IV offers superior tolerability and faster infusion times compared to traditional NAD+ IVs, helping to improve cellular function, metabolic health, and markers of aging.
Shoals Technologies Group And 2 Other Stocks That May Be Priced Below Their Estimated Worth
This article identifies Shoals Technologies Group (SHLS), Hasbro (HAS), and Sportradar Group (SRAD) as potentially undervalued stocks based on discounted cash flow analysis, even as the U.S. market faces fluctuations. Shoals Technologies Group is noted for its anticipated high earnings growth and innovation despite share price volatility. Hasbro is highlighted for its expected earnings growth and strategic relocation, while Sportradar Group shows strong financial health and market position through strategic partnerships and AI leverage.
Exact Sciences And 2 Other Stocks Estimated To Be Trading Below Their Fair Value
This article identifies Exact Sciences (EXAS), Equifax (EFX), and Oracle (ORCL) as three stocks trading below their estimated fair value, offering potential opportunities for investors. Despite recent market fluctuations, these companies show strong financial attributes and strategic growth initiatives that could enhance future cash flows and profitability. The analysis is based on discounted cash flow valuations and recent earnings reports.
Three Stocks Estimated To Be Undervalued In September 2025
Amidst a rising U.S. stock market and hopes for interest rate cuts, this article identifies three undervalued stocks based on discounted cash flow analysis: Global-E Online (GLBE), Ramaco Resources (METC), and StoneCo (STNE). Each company is trading significantly below its estimated fair value and shows potential for future profit growth, despite some individual challenges like shareholder dilution or debt concerns.
Three Stocks That May Be Undervalued In August 2025
Amidst a bullish U.S. stock market in late August 2025, this article identifies three potentially undervalued stocks: Hesai Group (HSAI), e.l.f. Beauty (ELF), and Glaukos Corporation (GKOS). Each company is trading at a significant discount to its estimated fair value based on discounted cash flow analysis, despite individual risks like stock volatility, insider selling, or low forecasted return on equity. The report emphasizes the growth potential for these companies, supported by strong revenue growth, recent profitability, or positive earnings forecasts.
The NAD⁺ liposome problem: supplement science vs marketing claims
A recent analysis of 21 top-selling NAD⁺ supplements revealed significant discrepancies between product claims and actual content, with most products containing less than 1% of advertised NAD⁺ or none at all. The report highlights critical quality control issues and questions the validity of liposomal claims due to technical challenges in formulation and verification. The article stresses the need for greater transparency and scientific validation in the supplement industry to prevent misleading consumers.
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
Niagen Bioscience has launched Tru Niagen® as an in-room amenity and Niagen IV through NutriDrip at the Equinox Hotel New York. These products, powered by Niagen’s patented nicotinamide riboside (NR), aim to support cellular energy production and DNA repair for optimal recovery. This partnership expands consumer access to their NAD+-boosting solutions within a luxury hospitality setting.
Niagen Bioscience signs exclusive licence deal for PD therapy
Niagen Bioscience has secured an exclusive global license with Haukeland University Hospital for developing a Parkinson's disease treatment using its patented nicotinamide riboside (Niagen) molecule. This agreement grants the company rights to intellectual property for regulatory filings in the EU and includes access to scientific data from the NOPARK trial, the largest clinical investigation of NAD+ augmentation in early PD. Niagen Bioscience aims to commercialize the drug candidate independently or through a strategic pharmaceutical partner.
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
Niagen Bioscience has secured an exclusive worldwide license with Haukeland University Hospital in Bergen, Norway, to develop and commercialize its patented nicotinamide riboside (Niagen®) as a potential treatment for Parkinson's Disease. This agreement is built upon years of joint research, including data from the recently completed NOPARK trial, the largest clinical investigation of NAD+ augmentation for early PD. The goal is to advance NAD+-boosting therapies toward regulatory approval and market availability for neurodegenerative diseases.
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
Niagen Bioscience, Inc. (formerly ChromaDex Corp.) announced the expansion of its pharmaceutical-grade Niagen® IV and injection availability to almost 600 clinics nationwide. Niagen IV, featuring patented nicotinamide riboside (NR), offers superior tolerability, a shorter infusion time, and a 20% higher increase in NAD+ levels compared to traditional NAD+ IVs. Several clinic providers praised Niagen IV for its effectiveness in improving athletic performance, cellular energy, brain health, and overall wellness.
Supplement Maker Rebrands
Westwood-based dietary supplement company ChromaDex Corp. has rebranded as Niagen Bioscience Inc., changing its Nasdaq ticker to NAGE. This move aligns the company's identity with its core product, Niagen, a supplement designed to reduce the health impacts of aging by boosting NAD+ levels. CEO Rob Fried stated that the rebranding signifies a turning point, reflecting scientific, financial, and strategic milestones, and aiming to enhance partnerships and global reach.
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
Niagen Bioscience has affirmed that its operations and products, including its patented nicotinamide riboside (NR) ingredient Niagen®, are not impacted by recent global tariffs. The company attributes this resilience to its U.S.-based manufacturing and supply chain, with most of its materials sourced domestically. Additionally, key international sales, like those to A.S. Watson in Hong Kong, operate in duty-free markets, ensuring these revenue streams also remain unaffected.
Check out Niagen Bioscience's stock price (NAGE) in real time
This article provides real-time stock information for Niagen Bioscience Inc (NAGE), including its current stock price, volume, 52-week range, and key financial metrics. It also offers a company profile, recent news, and insights into its management and business focus on NAD+ research and dietary supplements.
ChromaDex rebrands as Niagen Bioscience to reflect growth in supplement, pharmaceutical industries
ChromaDex, known for its focus on NAD+ and its Niagen ingredient, has rebranded as Niagen Bioscience to better reflect its expanding mission beyond just selling supplements. The company aims to highlight Niagen as a strong and trustworthy brand in the NAD space and expand into both dietary supplement and pharmaceutical industries. Niagen Bioscience sees significant therapeutic potential in addressing neurodegenerative diseases and has introduced Niagen Plus, a pharmaceutical-grade IV Niagen available by prescription.
